Thermo Fisher Scientific (NYSE: TMO) and Cogentix Medical (NASDAQ:CGNT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.
Thermo Fisher Scientific pays an annual dividend of $0.60 per share and has a dividend yield of 0.3%. Cogentix Medical does not pay a dividend. Thermo Fisher Scientific pays out 10.5% of its earnings in the form of a dividend.
This is a summary of current ratings for Thermo Fisher Scientific and Cogentix Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Thermo Fisher Scientific||0||1||14||1||3.00|
Thermo Fisher Scientific presently has a consensus target price of $193.36, suggesting a potential upside of 0.78%. Given Thermo Fisher Scientific’s higher probable upside, equities research analysts plainly believe Thermo Fisher Scientific is more favorable than Cogentix Medical.
Insider and Institutional Ownership
83.4% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 12.7% of Cogentix Medical shares are owned by institutional investors. 0.5% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 35.5% of Cogentix Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Thermo Fisher Scientific has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Cogentix Medical has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.
This table compares Thermo Fisher Scientific and Cogentix Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Thermo Fisher Scientific||11.80%||15.97%||7.48%|
Valuation & Earnings
This table compares Thermo Fisher Scientific and Cogentix Medical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Thermo Fisher Scientific||$19.20 billion||3.90||$4.81 billion||$5.74||33.43|
|Cogentix Medical||$53.65 million||3.34||$3.20 million||($0.41)||-7.17|
Thermo Fisher Scientific has higher revenue and earnings than Cogentix Medical. Cogentix Medical is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Thermo Fisher Scientific beats Cogentix Medical on 13 of the 15 factors compared between the two stocks.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables. The Analytical Instruments segment provides a range of instruments, consumables, software and services. The Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. The Laboratory Products and Services segment offers controlled temperature technologies products, growth protection and separation products, and water and laboratory products.
Cogentix Medical Company Profile
Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.